Ipamorelin vs GHRP-2 and GHRP-6 GHRP Family Side-by-Side Feature Receptor Ipamorelin GHS-R1a GHRP-2 GHS-R1a GHRP-6 GHS-R1a Feature Half-life Ipamorelin ~2 hours GHRP-2 ~25-30 minutes GHRP-6 ~20-30 minutes Feature Dosing Ipamorelin 1-3x daily (SubQ) GHRP-2 2-3x daily (SubQ) GHRP-6 2-3x daily (SubQ) Feature Standard dose Ipamorelin 100-300 mcg GHRP-2 100-300 mcg GHRP-6 100-300 mcg Feature Cortisol effect Ipamorelin None at standard doses GHRP-2 Yes GHRP-6 Yes Feature Prolactin effect Ipamorelin None GHRP-2 Moderate GHRP-6 Minimal Feature Appetite effect Ipamorelin Mild GHRP-2 Moderate GHRP-6 Strong Feature FDA status Ipamorelin Not approved GHRP-2 Not approved GHRP-6 Not approved All three target the same receptor
If the right micronutrients are available in sufficient form, it is produced by the body itself
In 2019, the United States Food and Drug Administration (FDA) documented adverse events in seven patients who received intravenous injections containing L-glutathione 200mg/mL compounded by a pharmacy using L-glutathione
Seizure medications: Some anticonvulsants affect B vitamin metabolism
The contrast is the whole point: clearance first, medical-grade product, blood-sugar and lab monitoring, and a provider who'll pull the plug if something looks off
Everolimus added to adjuvant endocrine therapy in patients with high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer